BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

972 related articles for article (PubMed ID: 29063518)

  • 1. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
    Hey JA; Yu JY; Versavel M; Abushakra S; Kocis P; Power A; Kaplan PL; Amedio J; Tolar M
    Clin Pharmacokinet; 2018 Mar; 57(3):315-333. PubMed ID: 29063518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain.
    Hey JA; Kocis P; Hort J; Abushakra S; Power A; Vyhnálek M; Yu JY; Tolar M
    CNS Drugs; 2018 Sep; 32(9):849-861. PubMed ID: 30076539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer's Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data.
    Kocis P; Tolar M; Yu J; Sinko W; Ray S; Blennow K; Fillit H; Hey JA
    CNS Drugs; 2017 Jun; 31(6):495-509. PubMed ID: 28435985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential.
    Abushakra S; Porsteinsson A; Scheltens P; Sadowsky C; Vellas B; Cummings J; Gauthier S; Hey JA; Power A; Wang P; Shen L; Tolar M
    J Prev Alzheimers Dis; 2017; 4(3):149-156. PubMed ID: 29182706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.
    Tolar M; Abushakra S; Hey JA; Porsteinsson A; Sabbagh M
    Alzheimers Res Ther; 2020 Aug; 12(1):95. PubMed ID: 32787971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
    Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
    CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.
    Guo B; Wu X; Zhang Y; Shi Y; Yu J; Cao G; Zhang J
    Clin Drug Investig; 2012 Jul; 32(7):475-86. PubMed ID: 22650326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers.
    Lin CC; Philips L; Xu C; Yeh LT
    J Clin Pharmacol; 2004 Mar; 44(3):265-75. PubMed ID: 14973309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
    Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
    Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, Tolerability, Pharmacokinetics and Quantitative Electroencephalography Assessment of ACD856, a Novel Positive Allosteric Modulator of Trk-Receptors Following Multiple Doses in Healthy Subjects.
    Önnestam K; Nilsson B; Rother M; Rein-Hedin E; Bylund J; Anderer P; Kemethofer M; Halldin MM; Sandin J; Segerdahl M
    J Prev Alzheimers Dis; 2023; 10(4):778-789. PubMed ID: 37874100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
    Vaughan D; Speed J; Medve R; Andrews JS
    Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials.
    Godfrey AR; Digiacinto J; Davis MW
    Clin Ther; 2011 Jun; 33(6):766-75. PubMed ID: 21704241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and tolerability of extended-release clarithromycin.
    Guay DR; Gustavson LE; Devcich KJ; Zhang J; Cao G; Olson CA
    Clin Ther; 2001 Apr; 23(4):566-77. PubMed ID: 11354390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of valiltramiprosate (ALZ-801) for the treatment of Alzheimer's disease: a novel small molecule with disease modifying potential.
    Lee D; Antonsdottir IM; Clark ED; Porsteinsson AP
    Expert Opin Pharmacother; 2024 May; ():1-9. PubMed ID: 38814590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 2 study of tramiprosate for cerebral amyloid angiopathy.
    Greenberg SM; Rosand J; Schneider AT; Creed Pettigrew L; Gandy SE; Rovner B; Fitzsimmons BF; Smith EE; Edip Gurol M; Schwab K; Laurin J; Garceau D
    Alzheimer Dis Assoc Disord; 2006; 20(4):269-74. PubMed ID: 17132972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects.
    Cheung D; Fong A; Ding HT; Cabanski CR; Wang J; Chen Y; Bush J; Harris JM; Pan L
    Pulm Pharmacol Ther; 2021 Aug; 69():102051. PubMed ID: 34166834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Single and Multiple Ascending Doses of BI 1358894 in Healthy Male Volunteers on Safety, Tolerability and Pharmacokinetics: Two Phase I Partially Randomised Studies.
    Fuertig R; Goettel M; Herich L; Hoefler J; Wiebe ST; Sharma V
    CNS Drugs; 2023 Dec; 37(12):1081-1097. PubMed ID: 38019355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical studies of the advanced glycation end-product (AGE)-breaker TRC4186: safety, tolerability and pharmacokinetics in healthy subjects.
    Chandra KP; Shiwalkar A; Kotecha J; Thakkar P; Srivastava A; Chauthaiwale V; Sharma SK; Cross MR; Dutt C
    Clin Drug Investig; 2009; 29(9):559-75. PubMed ID: 19663519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects.
    Li M; Shi A; Pang H; Xue W; Li Y; Cao G; Yan B; Dong F; Li K; Xiao W; He G; Du G; Hu X
    J Ethnopharmacol; 2014 Oct; 156():210-5. PubMed ID: 25219601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.